Results 141 to 150 of about 45,216 (237)

Ficus pandurata as a Functional Phytotherapeutic: Inhibiting JAK2/STAT3 Signaling and Activating Mitochondrial Apoptosis in Hepatocellular Carcinoma

Food Science &Nutrition, Volume 13, Issue 11, November 2025.
Triterpenoid‐ and coumarin‐rich Ficus pandurata Hance petroleum ether extract (FPHPE) significantly inhibited HepG2, SMMC7721, and Hep3B proliferation and suppressed tumor burden in xenograft mice without systemic toxicity. Comprehensive validation confirmed mitochondria‐mediated apoptosis through Annexin V/PI flow cytometry, Western blot, TEM ...
Muhammad Majid, Bing Tang, Yingyao Lai, Xiaoyan Pang, Yongdui Ruan, Hui Shi, Weiwen Peng, Weibo Dai, Xianjing Hu   +8 more
wiley   +1 more source

Cancer‐Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy

MedComm, Volume 6, Issue 11, November 2025.
This review explores the multifaceted roles of cancer‐associated fibroblasts (CAFs) in tumor biology. It examines their diverse origins, dynamic activation via signaling pathways, and spatial–temporal heterogeneity, proposing an updated classification of eight distinct CAF subtypes. The review highlights CAFs' contributions to tumor growth, metastasis,
Chang Fan, Wenlong Zhu, Yuan Chen, Wanwan Zhu, Jin Ding   +4 more
wiley   +1 more source

Exosomal miR-6126 as a novel therapeutic target for overcoming resistance of anti-cancer effect in hepatocellular carcinoma

BMC Cancer
Background Hepatocellular carcinoma (HCC) stands as the sixth most prevalent cancer globally, presenting a substantial health challenge, particularly due to late-stage diagnoses that limit treatment effectiveness.
Hyemin Hwang, Jimin Kim, Tae-Hun Kim, Yeonju Han, Dayoung Choi, Sua Cho, Seunghwan Kim, Sanghee Park, Taehyun Park, Filippo Piccinini, Won Jong Rhee, Jae-Chul Pyun, Misu Lee   +12 more
doaj   +1 more source

Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management

MedComm, Volume 6, Issue 11, November 2025.
Thyroid cancer risk is influenced by both genetic and modifiable factors, including mutations, radiation exposure, lifestyle, and pre‐existing benign conditions. Diagnosis involves physical exams, ultrasound, scintigraphy, laboratory tests, and fine‐needle aspiration biopsy (FNAB).
Yu‐Dong Li, Qing‐Yao Ye, Yan‐Xing Chen, Xia‐Rong Hu   +3 more
wiley   +1 more source

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma [PDF]

, 2021
Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Kensei Nishida, Tetsu Tomonari, Misato Hirata, Masahiro Bando, Yoshifumi Kida, Takahiro Tanaka, Tomoyuki Kawaguchi, Hironori Wada, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshihito Tanahashi, Tetsuji Takayama   +16 more
openalex   +1 more source

Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin‐TGFβ signalling

British Journal of Pharmacology, Volume 182, Issue 22, Page 5517-5535, November 2025.
Abstract Background and Purpose Hepatocellular carcinoma (HCC), the third leading cause of cancer‐related deaths worldwide, has limited treatment options and high mortality rate. We previously used a bioinformatics approach to identify niclosamide (NIC) as a promising repurposed drug candidate for HCC.
Mingdian Tan, Wei Ye, Yi Liu, Xiaowu Chen, Lakshmi Huttad, Mei‐Sze Chua, Samuel So   +6 more
wiley   +1 more source

Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p [PDF]

, 2022
Ying Gao, Zheng Yin, Yunling Qi, Hong Peng, Wenbin Ma, Ruizhi Wang, Wen Li   +6 more
openalex   +1 more source

Supplementary Figure Legends 1-2 from Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation [PDF]

, 2023
Jurjen S. Lagas, Robert A.B. van Waterschoot, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, Alfred H. Schinkel   +5 more
openalex   +2 more sources

αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma

, 2013
Xiaoyong Huang, Ai‐Wu Ke, Guo‐Ming Shi, Xin Zhang, Chi Zhang, Ying‐Hong Shi, Xiaoying Wang, Zhen‐Bin Ding, Yongsheng Xiao, Jun Yan, Shuang‐Jian Qiu, Jia Fan, Jian Zhou   +12 more
openalex   +1 more source

Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma

Biology Direct
Background Hepatocellular carcinoma (HCC) is one of the most common as well as leading causes of mortality worldwide, and sorafenib is the first-line treatment in HCC patients. Unfortunately, drug resistance to sorafenib often develops.
Xiangbo Huang, Nan Yi, Pengfei Zhu, Jian Gao, Jun Lv   +4 more
doaj   +1 more source